Integrated Filing — IndAS



General information about company

Scrip Code 544319
NSE Symbol SENORES
MSEI Symbol NOTLISTED
ISIN INE0RB801010
Name of company SENORES PHARMACEUTICALS LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2026
Date of end of financial year 31-03-2027
Date of board meeting when results were approved 29-10-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 22-10-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Second quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Single segment
Description of single segment Pharmaceuticals
Start date and time of board meeting 29-10-2026   12:00:00
End date and time of board meeting 29-10-2026   13:30:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 28-03-2026
Indicate Company website link for updated RPT policy of the Company https://senorespharma.com/policies/
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? Yes
No. of times funds raised during the quarter 2
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
Not Applicable



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 3,565.00 6,264.00
Other income 1,476.00 2,431.00
Total income 5,041.00 8,695.00
2 Expenses
(a) Cost of materials consumed 816.00 1,563.00
(b) Purchases of stock-in-trade 469.00 888.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (5.00) 44.00
(d) Employee benefit expense 1,208.00 2,218.00
(e) Finance costs 222.00 444.00
(f) Depreciation, depletion and amortisation expense 393.00 754.00
(f) Other Expenses
1 Other Expenses 971.00 1,678.00
Total other expenses 971.00 1,678.00
Total expenses 4,074.00 7,589.00
3 Total profit before exceptional items and tax 967.00 1,106.00
4 Exceptional items 0.00 0.00
5 Total profit before tax 967.00 1,106.00
6 Tax expense
7 Current tax 201.00 232.00
8 Deferred tax (6.00) (1.00)
9 Total tax expenses 195.00 231.00
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 772.00 875.00
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 772.00 875.00
17 Other comprehensive income net of taxes 0.00 0.00
18 Total Comprehensive Income for the period 772.00 875.00
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 4,605.00 4,605.00
Face value of equity share capital 10 10
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 1.68 1.9
Diluted earnings (loss) per share from continuing operations 1.67 1.89
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 1.68 1.9
Diluted earnings (loss) per share from continuing and discontinued operations 1.67 1.89
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2026
Date of end of reporting period 30-09-2026
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 10,933.00
Capital work-in-progress 635.00
Investment property 0.00
Goodwill 0.00
Other intangible assets 0.00
Intangible assets under development 473.00
Biological assets other than bearer plants 0.00
Investments accounted for using equity method
Non-current financial assets
Non-current investments 15,462.00
Trade receivables, non-current
Loans, non-current 42,286.00
Other non-current financial assets
1 Other Financial Assets 1,434.00
Total of other non-current financial assets 1,434.00
Total non-current financial assets 59,182.00
Deferred tax assets (net) 155.00
Other non-current assets
1 Other Non-Current Assets 113.00
Total of other non-current assets 113.00
Total non-current assets 71,491.00
2 Current assets
Inventories 989.00
Current financial asset
Current investments 0.00
Trade receivables, current 6,669.00
Cash and cash equivalents 1,131.00
Bank balance other than cash and cash equivalents 8,238.00
Loans, current 0.00
Other current financial assets
Total of other current financial assets 373.00
Total current financial assets 16,411.00
Current tax assets (net)
Other current assets
1 Other Current Assets 2,922.00
Total of other current assets 2,922.00
Total current assets 20,322.00
3 Non-current assets classified as held for sale 0.00
4 Regulatory deferral account debit balances and related deferred tax Assets 0.00
Total assets 91,813.00
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 4,605.00
Other equity 71,261.00
Total equity attributable to owners of parent 75,866.00
Non controlling interest
Total equity 75,866.00
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 5,572.00
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises
Total Trade payable
Other non-current financial liabilities
1 Lease Liabilities 1,807.00
Total of other non-current financial liabilities 1,807.00
Total non-current financial liabilities 7,379.00
Provisions, non-current 349.00
Deferred tax liabilities (net)
Deferred government grants, Non-current
Other non-current liabilities
Total of other non-current liabilities
Total non-current liabilities 7,728.00
Current liabilities
Current financial liabilities
Borrowings, current 3,382.00
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 312.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 2,598.00
Total Trade payable 2,910.00
Other current financial liabilities
1 Lease Liabilities 253.00
2 Other Financial Liabilities 572.00
Total of other current financial liabilities 825.00
Total current financial liabilities 7,117.00
Other current liabilities 132.00
1 Other Current Liabilities 132.00
Total of other current liabilities 132.00
Provisions, current 372.00
Current tax liabilities (Net) 598.00
Deferred government grants, Current 0.00
Total current liabilities 8,219.00
3 Liabilities directly associated with assets in disposal group classified as held for sale
4 Regulatory deferral account credit balances and related deferred tax liability
Total liabilities 15,947.00
Total equity and liabilites 91,813.00
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-07-2026 01-04-2026
Date of end of reporting period 30-09-2026 30-09-2026
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Items that will not be reclassified subsequently to profit or loss 0.00 0.00
Total Amount of items that will not be reclassified to profit and loss 0.00 0.00
2 Income tax relating to items that will not be reclassified to profit or loss 0.00 0.00
3 Amount of items that will be reclassified to profit and loss
1 Items that will be reclassified to profit or loss 0.00 0.00
Total Amount of items that will be reclassified to profit and loss 0.00 0.00
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income 0.00 0.00



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026
B Date of end of reporting period 30-09-2026
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 1,106.00
Adjustments for reconcile profit (loss)
Adjustments for finance costs 444.00
Adjustments for decrease (increase) in inventories (14.00)
Adjustments for decrease (increase) in trade receivables, current 977.00
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets (580.00)
Adjustments for decrease (increase) in other non-current assets 0.00
Adjustments for other financial assets, non-current 0.00
Adjustments for other financial assets, current (367.00)
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current (233.00)
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities (9.00)
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 754.00
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current 323.00
Adjustments for provisions, non-current (115.00)
Adjustments for other financial liabilities, current 90.00
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains (36.00)
Adjustments for dividend income 0.00
Adjustments for interest income 1,929.00
Adjustments for share-based payments 0.00
Adjustments for fair value losses (gains) 0.00
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 0.00
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items 0.00
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) (695.00)
Net cash flows from (used in) operations 411.00
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 97.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 314.00
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 0.00
Purchase of property, plant and equipment 2,271.00
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 6,151.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 1,929.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 2,057.00
Net cash flows from (used in) investing activities (4,436.00)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 1,803.00
Repayments of borrowings 0.00
Payments of lease liabilities (672.00)
Dividends paid 0.00
Interest paid 444.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities 2,031.00
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes (2,091.00)
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents (2,091.00)
Cash and cash equivalents cash flow statement at beginning of period 3,222.00
Cash and cash equivalents cash flow statement at end of period 1,131.00





Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)

Amount in (Lakhs)

Mode of Fund Raising Public Issues
Description of mode of fund raising (Applicable in case of others is selected)
Date of Raising Funds 26-12-2024
Amount Raised 50,000.00
Report filed for Quarter ended 30-09-2026
Monitoring Agency Applicable
Monitoring Agency Name, if applicable CARE Ratings Limited
Is there a Deviation / Variation in use of funds raised No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders
If Yes, Date of shareholder Approval
Explanation for the Deviation / Variation Not Applicable
Comments of the Audit Committee after review Not Applicable
Comments of the auditors, if any Not Applicable
Sr. Original Object Modified Object, if any Original Allocation Modified allocation, if any Funds Utilised Amount of Deviation/Variation for the quarter according to applicable object Remarks if any
1 Investment in one of our Subsidiaries, Havix, to fund capital expenditure requirements for setting up a manufacturing facility for the production of sterile injections in our Atlanta Facility Not applicable 10,700.00 4,198.00 698.00 0.00
2 Re-payment/pre-payment, in full or in part, of certain borrowings availed by our Company Not applicable 7,348.00 7,310.00 7,310.00 0.00
3 Investment in our Subsidiary, namely, Havix, for re- payment/pre-payment in full or in part, of certain borrowings availed by such Subsidiaries Not applicable 2,022.00 2,020.00 2,020.00 0.00
4 Funding the working capital requirements of our Company Not applicable 4,326.00 0.00 4,326.00 0.00
5 Investment in our Subsidiaries, namely, SPI and Ratnatris to fund their working capital requirements Not applicable 5,948.00 0.00 5,948.00 0.00
6 Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes Not applicable 15,437.00 16,191.00 16,191.00 0.00
7 Offer expenses Not applicable 4,219.00 3,504.00 3,499.00 0.00
8 Investment in subsidiary SPI to fund the acquisition of ANDAs. Not applicable 0.00 1,539.00 1,007.00 0.00
9 Investment in one of the subsidiaries, Apnar, to fund the capital expenditure requirements for expansion of its existing manufacturing facility in Vadodara. Not applicable 0.00 2,500.00 169.00 0.00
10 Investment in one of the subsidiaries, Havix, to fund the capital expenditure requirements for expansion of the existing OSD manufacturing facility in Atlanta. Not applicable 0.00 2,463.00 714.00 0.00


Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (2)

Amount in (Lakhs)

Mode of Fund Raising Preferential Issues
Description of mode of fund raising (Applicable in case of others is selected)
Date of Raising Funds 28-03-2026
Amount Raised 9,500.00
Report filed for Quarter ended 30-09-2026
Monitoring Agency Not Applicable
Monitoring Agency Name, if applicable
Is there a Deviation / Variation in use of funds raised No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders
If Yes, Date of shareholder Approval
Explanation for the Deviation / Variation false
Comments of the Audit Committee after review No Comments
Comments of the auditors, if any No Comments
Sr. Original Object Modified Object, if any Original Allocation Modified allocation, if any Funds Utilised Amount of Deviation/Variation for the quarter according to applicable object Remarks if any
1 Funding the working Capital requirements of our company Not applicable 31,25,30,00,000.00 0.00 6,84,00,00,000.00 0.00
2 Funding the product development expenditure for the company Not applicable 25,00,00,00,000.00 0.00 0.00 0.00
3 Investment in our subsidiaries, by way of loan, to fund their working capital requirements Not applicable 15,00,00,00,000.00 0.00 6,15,01,00,000.00 0.00
4 General Corporate Purpose Not applicable 23,75,10,00,000.00 0.00 3,92,09,00,000.00 0.00


Signatory Details

Name of signatory Deval Rajnikant Shah
Designation of person Chief Financial Officer
Place Ahmedabad
Date 29-10-2026




Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Havix Group Inc Havenbricks Properties LLC Promoter and Key Managerial Personnel Any other transaction Rent Expense Approved 36.00 0.00 0.00
2 Havix Group Inc Ashokbhai Vijaysinh Barot Key Managerial Personnel Remuneration Approved 26.00 0.00 0.00
3 Senores Pharmaceuticals Ltd Remus Pharmaceuticals pvt Ltd Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Sale of goods or services Approved 9.00 0.00 0.00
4 Senores Pharmaceuticals Ltd Remus Pharmaceuticals pvt Ltd Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Interest paid Approved 7.00 0.00 0.00
5 Senores Pharmaceuticals Ltd Remus Pharmaceuticals pvt Ltd Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Any other transaction Recovery of Expenses Approved 61.00 0.00 0.00
6 Senores Pharmaceuticals Ltd Renosen Pharmaceuticals Pvt Ltd. Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Purchase of goods or services Approved 40.00 0.00 0.00
7 Senores Pharmaceuticals Ltd Senores Biologics Private Limited Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Any other transaction Rent Income Approved 1.00 0.00 0.00
8 Senores Pharmaceuticals Ltd Senores Biologics Private Limited Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Sale of goods or services Approved 60.00 0.00 0.00
9 Senores Pharmaceuticals Ltd Senores Biologics Private Limited Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Any other transaction Loan Taken Approved 275.00 0.00 0.00
10 Senores Pharmaceuticals Ltd Senores Biologics Private Limited Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Any other transaction Loan Repayment Approved 50.00 0.00 0.00
11 Senores Pharmaceuticals Ltd Senores Biologics Private Limited Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Interest paid Approved 4.00 0.00 0.00
12 Senores Pharmaceuticals Ltd Amerisyn Step down Subsidiary Sale of goods or services Approved 8.00 0.00 0.00
13 Senores Pharmaceuticals Ltd Zoraya Step down Subsidiary Sale of goods or services Approved 29.00 0.00 0.00
14 Senores Pharmaceuticals Ltd Senores Biologics Private Limited Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Any other transaction Recovery of Expenses Approved 15.00 0.00 0.00
15 Senores Pharmaceuticals Ltd Aelius Projects LLP Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Any other transaction Rent Expense Approved 9.00 0.00 0.00
16 Senores Pharmaceuticals Ltd Aelius Projects LLP Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Any other transaction Property tax Approved 0.00 0.00 0.00
17 Senores Pharmaceuticals Ltd Aelius Projects LLP Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Any other transaction Repair & Maintance expense Approved 2.00 0.00 0.00
18 Senores Pharmaceuticals Ltd Espee Therapeutics Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Any other transaction Recovery of Expenses Approved 17.00 0.00 0.00
19 Senores Pharmaceuticals Ltd Espee Therapeutics Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Any other transaction Reimbursement of Expenses Approved 7.00 0.00 0.00
20 Senores Pharmaceuticals Ltd Tapan Shah Close relatives of Key Managerial Personnel Purchase of goods or services Approved 3.00 0.00 0.00
21 Senores Pharmaceuticals Ltd Swapnil J Shah Promoter and Key Managerial Personnel Remuneration Approved 375.00 0.00 0.00
22 Senores Pharmaceuticals Ltd Sanjay Majmudar & Assocaites Close relatives of Key Managerial Personnel Purchase of goods or services Approved 23.00 0.00 0.00
23 Senores Pharmaceuticals Ltd Espee Lifesciences Private Limited Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Sale of goods or services Approved 0.00 0.00 0.00
24 Senores Pharmaceuticals Ltd Espee Pharma UK Ltd Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Purchase of goods or services Approved 0.00 0.00 0.00
25 Senores Pharmaceuticals Ltd Espee Global Clinical Trial Services Private Limited Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Any other transaction Recovery of Expenses Approved 0.00 0.00 0.00
26 Senores Pharmaceuticals Ltd Havix Group Inc Subsidiary Company Interest received Approved 268.00 0.00 0.00
27 Senores Pharmaceuticals Ltd Havix Group Inc Subsidiary Company Loan Approved 733.00 0.00 0.00
28 Senores Pharmaceuticals Ltd Havix Group Inc Subsidiary Company Any other transaction Loan Repayment Approved 674.00 0.00 0.00
29 Senores Pharmaceuticals Ltd Havix Group Inc Subsidiary Company Any other transaction Recovery of Expenses Approved 179.00 0.00 0.00
30 Senores Pharmaceuticals Ltd Havix Group Inc Subsidiary Company Sale of goods or services Approved 1,114.00 0.00 0.00
31 Senores Pharmaceuticals Ltd Havix Group Inc Subsidiary Company Purchase of goods or services Approved 127.00 0.00 0.00
32 Senores Pharmaceuticals Ltd Havix Group Inc Subsidiary Company Sale of goods or services Approved 401.00 0.00 0.00
33 Senores Pharmaceuticals Ltd Havix Group Inc Subsidiary Company Sale of fixed assets Approved 3.00 0.00 0.00
34 Senores Pharmaceuticals Ltd Senores Pharmaceuticals Inc. Wholly owned Subsidiary company Interest received Approved 878.00 0.00 0.00
35 Senores Pharmaceuticals Ltd Senores Pharmaceuticals Inc. Wholly owned Subsidiary company Loan Approved 2,801.00 0.00 0.00
36 Senores Pharmaceuticals Ltd Senores Pharmaceuticals Inc. Wholly owned Subsidiary company Any other transaction Recovery of Expenses Approved 148.00 0.00 0.00
37 Senores Pharmaceuticals Ltd Senores Pharmaceuticals Inc. Wholly owned Subsidiary company Sale of goods or services Approved 1,036.00 0.00 0.00
38 Senores Pharmaceuticals Ltd Senores Pharmaceuticals Inc. Wholly owned Subsidiary company Sale of goods or services Approved 192.00 0.00 0.00
39 Senores Pharmaceuticals Ltd Ratnatris Pharmaceuticals pvt Ltd Subsidiary Company Loan Approved 0.00 0.00 0.00
40 Senores Pharmaceuticals Ltd Ratnatris Pharmaceuticals pvt Ltd Subsidiary Company Purchase of goods or services Approved 246.00 0.00 0.00
41 Senores Pharmaceuticals Ltd Ratnatris Pharmaceuticals pvt Ltd Subsidiary Company Interest received Approved 233.00 0.00 0.00
42 Senores Pharmaceuticals Ltd Ratnatris Pharmaceuticals pvt Ltd Subsidiary Company Purchase of goods or services Approved 46.00 0.00 0.00
43 Senores Pharmaceuticals Ltd Ratnatris Pharmaceuticals pvt Ltd Subsidiary Company Any other transaction Recovery of Expenses Approved 176.00 0.00 0.00
44 Senores Pharmaceuticals Ltd Ratnatris Pharmaceuticals pvt Ltd Subsidiary Company Sale of goods or services Approved 153.00 0.00 0.00
45 Senores Pharmaceuticals Ltd Ratnatris Pharmaceuticals pvt Ltd Subsidiary Company Sale of goods or services Approved 43.00 0.00 0.00
46 Senores Pharmaceuticals Ltd Apnar Pharma Pvt Ltd (From 16/Jan/2026) Subsidiary Company Sale of goods or services Approved 123.00 0.00 0.00
47 Senores Pharmaceuticals Ltd Apnar Pharma Pvt Ltd (From 16/Jan/2026) Subsidiary Company Purchase of fixed assets Approved 2.00 0.00 0.00
48 Senores Pharmaceuticals Ltd Apnar Pharma Pvt Ltd (From 16/Jan/2026) Subsidiary Company Sale of fixed assets Approved 0.00 0.00 0.00
49 Senores Pharmaceuticals Ltd Apnar Pharma Pvt Ltd (From 16/Jan/2026) Subsidiary Company Any other transaction Recovery of Expenses Approved 40.00 0.00 0.00
50 Senores Pharmaceuticals Ltd Apnar Pharma Pvt Ltd (From 16/Jan/2026) Subsidiary Company Any other transaction Reimbursement of Expenses Approved 2.00 0.00 0.00
51 Senores Pharmaceuticals Ltd Apnar Pharma Pvt Ltd (From 16/Jan/2026) Subsidiary Company Interest received Approved 177.00 0.00 0.00
52 Senores Pharmaceuticals Ltd Apnar Pharma Pvt Ltd (From 16/Jan/2026) Subsidiary Company Loan Approved 3,564.00 0.00 0.00
53 Senores Pharmaceuticals Ltd Apnar Pharma Pvt Ltd (From 16/Jan/2026) Subsidiary Company Any other transaction Repayment of loan Approved 1,843.00 0.00 0.00
54 Senores Pharmaceuticals Inc. Havix Group Inc Fellow Subsidiary Purchase of goods or services Approved 0.00 0.00 0.00
55 Senores Pharmaceuticals Inc. Havix Group Inc Fellow Subsidiary Any other transaction Recovery of Expenses Approved 0.00 0.00 0.00
56 Senores Pharmaceuticals Inc. Havix Group Inc Fellow Subsidiary Any other transaction Product Development Cost Approved 3,511.00 0.00 0.00
57 Apnar Pharma Pvt Ltd (From 16/Jan/2026) Senores Biologics Private Limited Close relatives of Key Managerial Personnel Any other transaction Investment Approved 176.00 0.00 176.00
58 Apnar Pharma Private Limited Havix Group Inc Fellow Subsidiary Sale of goods or services Approved 2,321.00 0.00 0.00
59 Senores Pharmaceuticals Ltd Zoraya Step down Subsidiary Any other transaction Outstanding Balances-Trade Receivable Approved 0.00 0.00 29.00
60 Havix Group Inc Apnar Pharma Private Limited Fellow Subsidiary Any other transaction Outstanding Balances-Trade Receivable Approved 0.00 0.00 99.00
61 Senores Pharmaceuticals Ltd Ratnatris Pharmaceuticals pvt Ltd Subsidiary Company Any other transaction Outstanding Balances-Interest Receivable Approved 0.00 350.00 233.00
62 Apnar Pharma Private Limited Havix Group Inc Fellow Subsidiary Purchase of fixed assets Approved 243.00 0.00 0.00
63 Apnar Pharma Private Limited Havix Group Inc Fellow Subsidiary Any other transaction Outside Lab Testing Approved 34.00 0.00 0.00
64 Ratnatris Pharmaceuticals Private Limited Jitendra Babulal Sanghvi Close relatives of Key Managerial Personnel Remuneration Approved 48.00 0.00 0.00
65 Ratnatris Pharmaceuticals Private Limited Jitendra Babulal Sanghvi Promoter and Key Managerial Personnel Any other transaction Loan Taken Approved 100.00 0.00 0.00
66 Ratnatris Pharmaceuticals Private Limited Babulal Misrimal Sanghavi Close relatives of Key Managerial Personnel Any other transaction Loan Taken Approved 100.00 0.00 0.00
67 Ratnatris Pharmaceuticals Private Limited Babulal Misrimal Sanghavi Close relatives of Key Managerial Personnel Interest paid Approved 58.00 0.00 0.00
68 Ratnatris Pharmaceuticals Private Limited Remus Pharmaceuticals pvt Ltd Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Interest paid Approved 21.00 0.00 0.00
69 Ratnatris Pharmaceuticals Private Limited Remus Pharmaceuticals pvt Ltd Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Sale of goods or services Approved 709.00 0.00 0.00
70 Apnar Pharma Private Limited Swapnil Patel Promoter and Key Managerial Personnel Remuneration Approved 18.00 0.00 0.00
71 Apnar Pharma Private Limited Senores Pharmaceuticals Inc. Fellow Subsidiary Any other transaction Product Development Cost Approved 425.00 0.00 0.00
72 Senores Pharmaceuticals Inc. Zoraya Fellow Subsidiary Investment Approved 98.00 0.00 0.00
73 Senores Pharmaceuticals Inc. Zoraya Fellow Subsidiary Loan Approved 48.00 0.00 0.00
74 Senores Pharmaceuticals Inc. Zoraya Fellow Subsidiary Interest received Approved 1.00 0.00 0.00
75 Senores Pharmaceuticals Ltd Senores Foundation Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Any other transaction CSR Contribution Approved 5.00 0.00 0.00
76 Senores Pharmaceuticals Inc. Amerisyn Fellow Subsidiary Investment Approved 67.00 0.00 0.00
77 Senores Pharmaceuticals Ltd Tapan Shah Close relatives of Key Managerial Personnel Any other transaction Outstanding Balances-Trade Payable Approved 0.00 0.00 0.00
78 Senores Pharmaceuticals Ltd Aelius Projects LLP Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Any other transaction Outstanding Balances-Trade Payable Approved 0.00 3.00 3.00
79 Senores Pharmaceuticals Ltd Espee Pharma UK Ltd Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Any other transaction Outstanding Balances-Trade Payable Approved 0.00 1.00 1.00
80 Senores Pharmaceuticals Ltd Espee Therapeutics LLP Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Any other transaction Outstanding Balances-Trade Receivable Approved 0.00 0.00 0.00
81 Senores Pharmaceuticals Ltd Havix Group INC Subsidiary Company Any other transaction Outstanding Balances-Non Current investments Approved 0.00 7,339.00 7,339.00
82 Senores Pharmaceuticals Ltd Havix Group INC Subsidiary Company Any other transaction Outstanding Balances-Loans & Advances Approved 0.00 6,290.00 5,914.00
83 Senores Pharmaceuticals Ltd Havix Group INC Subsidiary Company Any other transaction Outstanding Balances-Interest Receivable Approved 0.00 0.00 684.00
84 Senores Pharmaceuticals Ltd Havix Group INC Subsidiary Company Any other transaction Outstanding Balances-Trade Receivable Approved 0.00 2,775.00 1,578.00
85 Senores Pharmaceuticals Ltd Ratnatris Pharmaceuticals Private Limited Subsidiary Company Any other transaction Outstanding Balances-Non Current investments Approved 0.00 2,842.00 2,842.00
86 Senores Pharmaceuticals Ltd Ratnatris Pharmaceuticals Private Limited Subsidiary Company Any other transaction Outstanding Balances-Trade Receivable Approved 0.00 155.00 369.00
87 Senores Pharmaceuticals Ltd Ratnatris Pharmaceuticals Private Limited Subsidiary Company Any other transaction Outstanding Balances-Loans & Advances Approved 0.00 5,342.00 5,172.00
88 Senores Pharmaceuticals Ltd Ratnatris Pharmaceuticals Private Limited Subsidiary Company Any other transaction Outstanding Balances-Trade Payable Approved 0.00 131.00 103.00
89 Senores Pharmaceuticals Ltd Remus Pharmaceuticals Limited Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Any other transaction Outstanding Balances-Trade Receivable Approved 0.00 78.00 25.00
90 Senores Pharmaceuticals Ltd Senores Biologics Private Limited Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Any other transaction Outstanding Balances-Borrowings Approved 0.00 0.00 225.00
91 Senores Pharmaceuticals Ltd Remus Pharmaceuticals Limited Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Any other transaction Outstanding Balances-Borrowings Approved 0.00 169.00 169.00
92 Senores Pharmaceuticals Ltd Renosen Pharmaceuticals Pvt Ltd. Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Any other transaction Outstanding Balances-Trade Payable Approved 0.00 5.00 27.00
93 Senores Pharmaceuticals Ltd Apnar Pharma Private Limited Subsidiary Company Any other transaction Outstanding Balances-Trade Payable Approved 0.00 1,146.00 1,146.00
94 Senores Pharmaceuticals Ltd Senores Pharmaceuticals Inc. Wholly owned Subsidiary company Any other transaction Outstanding Balances-Non Current investments Approved 0.00 3,773.00 3,773.00
95 Senores Pharmaceuticals Ltd Senores Pharmaceuticals Inc. Wholly owned Subsidiary company Any other transaction Outstanding Balances-Trade Receivable Approved 0.00 2,346.00 1,467.00
96 Senores Pharmaceuticals Ltd Senores Pharmaceuticals Inc. Wholly owned Subsidiary company Any other transaction Outstanding Balances-Interest Receivable Approved 0.00 0.00 3,334.00
97 Senores Pharmaceuticals Ltd Apnar Pharma Private Limited Subsidiary Company Any other transaction Outstanding Balances-Loans & Advances Approved 0.00 2,206.00 3,953.00
98 Senores Pharmaceuticals Ltd Apnar Pharma Private Limited Subsidiary Company Any other transaction Outstanding Balances-Interest payable Approved 0.00 26.00 176.00
99 Senores Pharmaceuticals Ltd Senores Pharmaceuticals Inc. Wholly owned Subsidiary company Any other transaction Outstanding Balances-Loans & Advances Approved 0.00 22,255.00 22,814.00
100 Senores Pharmaceuticals Ltd Swapnil Jatinbhai Shah Promoter and Key Managerial Personnel Any other transaction Outstanding Balances-Payable on Employee benefits Approved 0.00 38.00 39.00
101 Ratnatris Pharmaceuticals Pvt Ltd Adroit Life Science Private Limited Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Any other transaction Outstanding Balances-Trade Receivable Approved 0.00 260.00 0.00
102 Ratnatris Pharmaceuticals Pvt Ltd Adroit Life Science Private Limited Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Any other transaction Outstanding Balances-Borrowings Approved 0.00 0.00 260.00
103 Ratnatris Pharmaceuticals Pvt Ltd Babulal Misrimal Sanghavi Close relatives of Key Managerial Personnel Any other transaction Outstanding Balances-Interest payable Approved 0.00 125.00 58.00
104 Ratnatris Pharmaceuticals Pvt Ltd Babulal Misrimal Sanghavi Close relatives of Key Managerial Personnel Any other transaction Outstanding Balances-Borrowings Approved 0.00 1,122.00 1,348.00
105 Ratnatris Pharmaceuticals Pvt Ltd Jitendra Babulal Sanghvi Promoter and Key Managerial Personnel Any other transaction Outstanding Balances-Borrowings Approved 0.00 0.00 100.00
106 Ratnatris Pharmaceuticals Pvt Ltd Jitendra Babulal Sanghvi Promoter and Key Managerial Personnel Any other transaction Outstanding Balances-Payable on Employee benefits Approved 0.00 6.00 5.00
107 Senores Pharmaceuticals Ltd Remus Pharmaceuticals Limited Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Any other transaction Outstanding Balances-Interest payable Approved 0.00 0.00 7.00
108 Senores Pharmaceuticals Ltd Senores Biologics Private Limited Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Any other transaction Outstanding Balances-Interest payable Approved 0.00 0.00 4.00
109 Ratnatris Pharmaceuticals Pvt Ltd Remus Pharmaceuticals Limited Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Any other transaction Outstanding Balances-Interest payable Approved 0.00 39.00 21.00
110 Ratnatris Pharmaceuticals Pvt Ltd Remus Pharmaceuticals Limited Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Any other transaction Outstanding Balances-Trade Payable Approved 0.00 0.00 90.00
111 Ratnatris Pharmaceuticals Pvt Ltd Remus Pharmaceuticals Limited Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Any other transaction Outstanding Balances-Borrowings Approved 0.00 482.00 522.00
112 Ratnatris Pharmaceuticals Pvt Ltd Remus Pharmaceuticals Limited Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Any other transaction Outstanding Balances-Trade Receivable Approved 0.00 212.00 402.00
113 Ratnatris Pharmaceuticals Pvt Ltd Renosen Pharmaceuticals Pvt Ltd. Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Any other transaction Outstanding Balances-Trade Receivable Approved 0.00 59.00 0.00
114 Ratnatris Pharmaceuticals Pvt Ltd Adroit Life Science Private Limited Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Any other transaction Outstanding Balances-Trade Payable Approved 0.00 0.00 100.00
115 Ratnatris Pharmaceuticals Pvt Ltd Adroit Life Science Private Limited Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Any other transaction Outstanding Balances-Interest payable Approved 0.00 0.00 18.00
116 Havix Group Inc Senores Pharmaceuticals Inc. Fellow Subsidiary Any other transaction Outstanding Balances-Trade Payable Approved 3,551.00 4,804.00 1,253.00
117 Senores Pharmaceuticals Ltd Espee Therapeutics LLP Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Any other transaction Outstanding Balances-Trade Payable Approved 0.00 9.00 0.00
118 Senores Pharmaceuticals Ltd Apnar Pharma Private Limited Subsidiary Company Any other transaction Outstanding Balances-Trade Receivable Approved 0.00 3.00 190.00
119 Senores Pharmaceuticals Ltd SENORES FOUNDATION Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Any other transaction Recovery of Expenses Approved 0.00 0.00 0.00
120 Senores Pharmaceuticals Ltd Senores Biologics Private Limited Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Any other transaction Outstanding Balances-Trade Receivable Approved 0.00 33.00 0.00
121 Senores Pharmaceuticals Ltd Aelius Projects LLP Enterprises over which Key Managerial Personnel and/or their Close relative exercise significant influence Any other transaction Outstanding Balances-Trade Receivable Approved 0.00 1.00 1.00
122 Senores Pharmaceuticals Ltd Apnar Pharma Private Limited Subsidiary Company Any other transaction Outstanding Balances-Trade Payable Approved 0.00 0.00 2.00
123 Senores Pharmaceuticals Inc Apnar Pharma Private Limited Fellow Subsidiary Any other transaction Outstanding Balances-Trade Payable Approved 0.00 0.00 158.00
124 Senores Pharmaceuticals Inc Apnar Pharma Private Limited Fellow Subsidiary Any other transaction Outstanding Balances-Trade Receivable Approved 0.00 121.00 122.00
125 Havix Group Inc Senores Pharmaceuticals Inc. Fellow Subsidiary Any other transaction Outstanding Balances-Trade Receivable Approved 0.00 1,362.00 0.00
126 Havix Group Inc Senores Pharmaceuticals Inc. Fellow Subsidiary Any other transaction Due to / Due From (Payable) Approved 0.00 0.00 1,320.00
127 Havix Group Inc Apnar Pharma Private Limited Fellow Subsidiary Any other transaction Outstanding Balances-Trade Payable Approved 0.00 0.00 2,270.00
128 Senores Pharmaceuticals Ltd Amerisyn LLC Step down Subsidiary Any other transaction Outstanding Balances-Trade Receivable Approved 0.00 0.00 8.00
129 Senores Pharmaceuticals Inc Zoraya Fellow Subsidiary Any other transaction Outstanding Balances-Loans & Advances Approved 0.00 0.00 48.00
130 Senores Pharmaceuticals Inc Zoraya Fellow Subsidiary Any other transaction Outstanding Balances-Interest Receivable Approved 0.00 0.00 1.00
131 Senores Pharmaceuticals Inc Zoraya Fellow Subsidiary Any other transaction Investment in subsidiaries Approved 0.00 0.00 147.00
132 Senores Pharmaceuticals Inc Amerisyn LLC Fellow Subsidiary Any other transaction Investment in subsidiaries Approved 0.00 0.00 67.00
Total value of transaction during the reporting period 27,793.00